In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors

Correction of neuropathology and protection against learning impairments in affected mice

Antonella Consiglio, Angelo Quattrini, Sabata Martino, Jean Charles Bensadoun, Diego Dolcetta, Alessandra Trojani, Giuliana Benaglia, Sergio Marchesini, Vincenzo Cestari, Alberto Oliverio, Claudio Bordignon, Luigi Naldini

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning impairments. We show that selective degeneration of hippocampal neurons is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.

Original languageEnglish
Pages (from-to)310-316
Number of pages7
JournalNature Medicine
Volume7
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Cerebroside-Sulfatase
Metachromatic Leukodystrophy
Gene therapy
Genetic Therapy
Learning
Lipidoses
Brain
Disease Vectors
Nerve Degeneration
Central Nervous System Diseases
Gene Silencing
Demyelinating Diseases
Germ Cells
Gene encoding
Neurology
Neurons
Phenotype
Genes
Neuropathology
Enzymes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors : Correction of neuropathology and protection against learning impairments in affected mice. / Consiglio, Antonella; Quattrini, Angelo; Martino, Sabata; Bensadoun, Jean Charles; Dolcetta, Diego; Trojani, Alessandra; Benaglia, Giuliana; Marchesini, Sergio; Cestari, Vincenzo; Oliverio, Alberto; Bordignon, Claudio; Naldini, Luigi.

In: Nature Medicine, Vol. 7, No. 3, 2001, p. 310-316.

Research output: Contribution to journalArticle

Consiglio, A, Quattrini, A, Martino, S, Bensadoun, JC, Dolcetta, D, Trojani, A, Benaglia, G, Marchesini, S, Cestari, V, Oliverio, A, Bordignon, C & Naldini, L 2001, 'In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice', Nature Medicine, vol. 7, no. 3, pp. 310-316. https://doi.org/10.1038/85454
Consiglio, Antonella ; Quattrini, Angelo ; Martino, Sabata ; Bensadoun, Jean Charles ; Dolcetta, Diego ; Trojani, Alessandra ; Benaglia, Giuliana ; Marchesini, Sergio ; Cestari, Vincenzo ; Oliverio, Alberto ; Bordignon, Claudio ; Naldini, Luigi. / In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors : Correction of neuropathology and protection against learning impairments in affected mice. In: Nature Medicine. 2001 ; Vol. 7, No. 3. pp. 310-316.
@article{1f49a6db581f4fc7a7fbc6cfe0539c70,
title = "In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice",
abstract = "Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning impairments. We show that selective degeneration of hippocampal neurons is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.",
author = "Antonella Consiglio and Angelo Quattrini and Sabata Martino and Bensadoun, {Jean Charles} and Diego Dolcetta and Alessandra Trojani and Giuliana Benaglia and Sergio Marchesini and Vincenzo Cestari and Alberto Oliverio and Claudio Bordignon and Luigi Naldini",
year = "2001",
doi = "10.1038/85454",
language = "English",
volume = "7",
pages = "310--316",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors

T2 - Correction of neuropathology and protection against learning impairments in affected mice

AU - Consiglio, Antonella

AU - Quattrini, Angelo

AU - Martino, Sabata

AU - Bensadoun, Jean Charles

AU - Dolcetta, Diego

AU - Trojani, Alessandra

AU - Benaglia, Giuliana

AU - Marchesini, Sergio

AU - Cestari, Vincenzo

AU - Oliverio, Alberto

AU - Bordignon, Claudio

AU - Naldini, Luigi

PY - 2001

Y1 - 2001

N2 - Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning impairments. We show that selective degeneration of hippocampal neurons is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.

AB - Metachromatic leukodystrophy (MLD) is a lipidosis caused by deficiency of arylsulfatase A (ARSA). Although the genetics of MLD are known, its pathophysiology is not understood. The disease leads to progressive demyelination and early death and no effective treatment is available. We used lentiviral vectors to deliver a functional ARSA gene (human ARSA) into the brain of adult mice with germ-line inactivation of the mouse gene encoding ARSA, As2. We report sustained expression of active enzyme throughout a large portion of the brain, with long-term protection from development of neuropathology and hippocampal-related learning impairments. We show that selective degeneration of hippocampal neurons is a central step in disease pathogenesis, and provide evidence that in vivo transfer of ARSA by lentiviral vectors reverts the disease phenotype in all investigated areas. Therefore, in vivo gene therapy offers a unique option for MLD and other storage diseases affecting the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=0035099437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035099437&partnerID=8YFLogxK

U2 - 10.1038/85454

DO - 10.1038/85454

M3 - Article

VL - 7

SP - 310

EP - 316

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -